Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage

Alfonso Ciccone, Mario Pozzi, Cristina Motto, Pietro Tiraboschi, Roberto Sterzi

Research output: Contribution to journalArticle

Abstract

Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.

Original languageEnglish
JournalNeurological Sciences
Volume29
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2008

    Fingerprint

Keywords

  • Hemostatic treatment
  • Primary intracerebral hemorrhage
  • Randomized controlled trial
  • Recombinant activated factor VII
  • Tranexamic acid

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this